Clay Siegall Purchases 62,500 Shares of Shattuck Labs (NASDAQ:STTK) Stock

Shattuck Labs, Inc. (NASDAQ:STTK) Director Clay Siegall bought 62,500 shares of the firm’s stock in a transaction that occurred on Tuesday, June 9th. The shares were purchased at an average cost of $4.00 per share, with a total value of $250,000.00. Following the acquisition, the director directly owned 318,608 shares of the company’s stock, valued at approximately $1,274,432. This trade represents a 24.40% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shattuck Labs Stock Up 18.2%

Shattuck Labs stock opened at $4.94 on Friday. Shattuck Labs, Inc. has a 52 week low of $0.71 and a 52 week high of $8.33. The company has a market capitalization of $378.80 million, a price-to-earnings ratio of -7.84 and a beta of 1.08. The stock has a 50-day moving average price of $6.35 and a 200 day moving average price of $4.94.

Shattuck Labs (NASDAQ:STTK) last released its earnings results on Thursday, May 7th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. During the same period last year, the company posted ($0.27) EPS. Research analysts anticipate that Shattuck Labs, Inc. will post -0.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on STTK. Jefferies Financial Group raised Shattuck Labs to an “outperform” rating and set a $7.00 target price for the company in a report on Friday, June 5th. TD Cowen reissued a “buy” rating on shares of Shattuck Labs in a report on Friday, March 6th. Citigroup raised Shattuck Labs from a “neutral” rating to a “buy” rating and set a $7.00 price target for the company in a report on Friday, June 5th. Weiss Ratings downgraded Shattuck Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 2nd. Finally, Wall Street Zen raised Shattuck Labs from a “hold” rating to a “buy” rating in a report on Saturday. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.00.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. OMERS ADMINISTRATION Corp lifted its holdings in Shattuck Labs by 25.7% in the first quarter. OMERS ADMINISTRATION Corp now owns 33,300 shares of the company’s stock valued at $214,000 after acquiring an additional 6,800 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Shattuck Labs by 5.4% in the first quarter. The Manufacturers Life Insurance Company now owns 142,300 shares of the company’s stock valued at $915,000 after buying an additional 7,244 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Shattuck Labs in the third quarter valued at approximately $38,000. Squarepoint Ops LLC purchased a new stake in shares of Shattuck Labs in the third quarter valued at approximately $46,000. Finally, Mallini Complete Financial Planning LLC purchased a new stake in shares of Shattuck Labs in the fourth quarter valued at approximately $83,000. 58.74% of the stock is owned by institutional investors and hedge funds.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.